[go: up one dir, main page]

AR026916A1 - Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales - Google Patents

Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales

Info

Publication number
AR026916A1
AR026916A1 ARP000106516A ARP000106516A AR026916A1 AR 026916 A1 AR026916 A1 AR 026916A1 AR P000106516 A ARP000106516 A AR P000106516A AR P000106516 A ARP000106516 A AR P000106516A AR 026916 A1 AR026916 A1 AR 026916A1
Authority
AR
Argentina
Prior art keywords
treatment
combination
gastrointestinal disorders
pharmaceutical combinations
preference
Prior art date
Application number
ARP000106516A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR026916A1 publication Critical patent/AR026916A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a una combinacion de un primer agente que incluye un agonista o antagonista del receptor de 5-HT4 o un antagonista delreceptor de 5-TH3, y un coagente, y a composiciones y formulaciones farmacéuticas que contienen la combinacion. La combinacion farmacéutica se puede emplearpara el tratamiento de movilidad gastrointestinal alterada, sensibilidad, secrecion, o desordenes abdominales. La dosificacion de preferencia es oral, y laadministracion de preferencia es uno o dos veces al día. El primer agente preferido es tegaserod.
ARP000106516A 1999-12-10 2000-12-07 Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales AR026916A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
AR026916A1 true AR026916A1 (es) 2003-03-05

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106516A AR026916A1 (es) 1999-12-10 2000-12-07 Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales

Country Status (30)

Country Link
EP (3) EP1286668B1 (es)
JP (1) JP2003523324A (es)
KR (1) KR100765579B1 (es)
CN (2) CN1310644C (es)
AR (1) AR026916A1 (es)
AT (1) ATE293971T1 (es)
AU (2) AU778869B2 (es)
BR (1) BR0016275A (es)
CA (1) CA2388959A1 (es)
CO (1) CO5261535A1 (es)
CZ (1) CZ300690B6 (es)
DE (1) DE60019814T2 (es)
DK (1) DK1286668T3 (es)
ES (1) ES2240229T3 (es)
HU (1) HUP0301122A3 (es)
IL (2) IL149496A0 (es)
MX (1) MXPA02005695A (es)
MY (1) MY133423A (es)
NO (1) NO20022680L (es)
NZ (2) NZ531489A (es)
PE (1) PE20011030A1 (es)
PL (1) PL202201B1 (es)
PT (1) PT1286668E (es)
RU (1) RU2264215C2 (es)
SG (1) SG152025A1 (es)
SK (1) SK8062002A3 (es)
TR (1) TR200402293T2 (es)
TW (1) TWI263496B (es)
WO (1) WO2001041748A2 (es)
ZA (1) ZA200204493B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
MXPA05007379A (es) 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
RS20050868A (sr) * 2003-05-27 2007-08-03 Altana Pharma Ag., Farmaceutske kombinacije inhibotora protonske pumpe i jedinjenje koje modifikuje gastrointestinalni motilitet
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
CA2573209A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
EP1853256A2 (en) * 2005-01-31 2007-11-14 Novartis AG Organic compounds
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007085357A1 (en) 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
CN101466368A (zh) * 2006-06-15 2009-06-24 诺瓦提斯公司 用于治疗或者预防胃损伤的仅包括替加色罗或者包括替加色罗与质子泵抑制剂组合的组合物
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
AU2008321395B2 (en) 2007-11-13 2013-03-14 Viropharma Biologics Llc Corticosteroid compositions
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3497128A2 (en) 2016-08-09 2019-06-19 Kymab Limited Anti-icos antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362756A (en) * 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
DE69226961T2 (de) * 1991-12-21 1999-04-29 Smithkline Beecham P.L.C., Brentford, Middlesex Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
CZ285535B6 (cs) * 1994-11-21 1999-08-11 Dainippon Pharmaceutical Co., Ltd. Deriváty 6-methoxy-1H-benzotriazol-5-karboxamidu, způsoby jejich výroby a farmaceutické preparáty na nich založené
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
HUP0301122A2 (hu) 2003-08-28
AU2672801A (en) 2001-06-18
EP1488788A1 (en) 2004-12-22
EP1286668A2 (en) 2003-03-05
CN1875966A (zh) 2006-12-13
MXPA02005695A (es) 2002-09-18
BR0016275A (pt) 2002-08-27
DE60019814T2 (de) 2006-03-02
PL355663A1 (en) 2004-05-04
NZ566800A (en) 2009-11-27
ZA200204493B (en) 2003-09-29
ATE293971T1 (de) 2005-05-15
SK8062002A3 (en) 2003-04-01
SG152025A1 (en) 2009-05-29
PE20011030A1 (es) 2001-10-31
AU778869B2 (en) 2004-12-23
CA2388959A1 (en) 2001-06-14
PT1286668E (pt) 2005-08-31
PL202201B1 (pl) 2009-06-30
NO20022680L (no) 2002-08-12
CO5261535A1 (es) 2003-03-31
IL149496A (en) 2009-12-24
CN1409634A (zh) 2003-04-09
EP1286668B1 (en) 2005-04-27
KR100765579B1 (ko) 2007-10-09
CZ300690B6 (cs) 2009-07-15
CZ20021967A3 (cs) 2002-08-14
DK1286668T3 (da) 2005-08-15
AU2005200797A1 (en) 2005-03-17
HUP0301122A3 (en) 2005-03-29
DE60019814D1 (de) 2005-06-02
ES2240229T3 (es) 2005-10-16
TWI263496B (en) 2006-10-11
RU2264215C2 (ru) 2005-11-20
TR200402293T2 (tr) 2004-10-21
CN1310644C (zh) 2007-04-18
KR20030016208A (ko) 2003-02-26
JP2003523324A (ja) 2003-08-05
WO2001041748A2 (en) 2001-06-14
WO2001041748A3 (en) 2002-12-19
IL149496A0 (en) 2002-11-10
RU2002118316A (ru) 2004-02-20
MY133423A (en) 2007-11-30
AU2005200797B2 (en) 2008-01-24
NZ531489A (en) 2005-09-30
EP1913944A1 (en) 2008-04-23
NO20022680D0 (no) 2002-06-06

Similar Documents

Publication Publication Date Title
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
EA200101026A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
AR020015A1 (es) Composiciones de celecoxib
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
IT1282352B1 (it) Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
HUP0001089A2 (hu) Gyógyászati készítmények férfiak erekciós zavarainak kezelésére
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
NO20030897D0 (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
MXPA04005420A (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1.
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
AR038858A1 (es) Combinacion
SE0001916D0 (sv) Novel formulation
ECSP003820A (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
WO2007071394A3 (en) Combination of a 5-ht4 agonist with a cholinesterase inhibitor
HUP0004461A2 (hu) Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények
HRP20090225T1 (hr) Farmaceutske kompozicije na bazi nk2 antagonista za pedijatrijsku primjenu
WO2004011029A3 (en) Pharmaceutical compositions for penis enlargement
MXPA02007641A (es) Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa

Legal Events

Date Code Title Description
FB Suspension of granting procedure